China To Impose Export-Licensing Requirement On Drug Industry
This article was originally published in PharmAsia News
China's State Food and Drug Administration is about to test a new system of controlling drug exports on 10 pharmaceutical categories, according to the agency's director. Shao Mingli told a national food and drug conference the system would cover pharmaceutical agents and materials used to make them, plus other materials qualified for producing drugs. The new rules would require drug makers to obtain a license and register the drugs they produce, and they would have to have official qualifications and written export approval from authorities before the products can be exported. Shao also vowed to continue a crackdown on bribery, negligence and other abuses linked to the agency. (Click here for more
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.